17h40 Anderson de Oliveira Galvão

Vigilância Ativa no Câncer de Próstata
Comparação dos Resultados com Tratamentos Locais
Conflito de Interesse
Nunca recebi qualquer forma de pagamento ou auxílio financeiro de
entidade pública ou privada para pesquisa ou desenvolvimento de métodos,
diagnósticos e terapêuticos ou ainda, honorários como consultor de indústria
farmacêutica.
NCCN – 3.2016
Vigilância Ativa
- Active Surveillance aims to achieve correct timing for
curative treatment.
Welty, C.J. et al
Bill-Axelson et al. The New England Journal of Medicine 07-2011 – SPCG-4
Bill-Axelson et al. The New England Journal of Medicine 07-2011 – SPCG-4
Bill-Axelson et al. The New England Journal of Medicine 07-2011 – SPCG-4
Timothy J. W. et al. The New England Journal of Medicine 07-2012 – PIVOT
Matthew et al. The New England Journal of Medicine 01-2013 - PCOS
Comparativo de Técnicas?
Klotz L. et al Journal of Clinical Oncology 01-2015
Godtman R. A. et al. European Urology 03-2016 In Press - Göteborg
Godtman R. A. et al. European Urology 03-2016 In Press - Göteborg
Stattin P. et al. J Natl Cancer Inst 07-2010 – NPCR of Sweden
Stattin P. et al. J Natl Cancer Inst 07-2010 – NPCR of Sweden
Stattin P. et al. J Natl Cancer Inst 07-2010 – NPCR of Sweden
Auffenberg G. B. et al. The Journal of Urology 05-2016 – Manuscript
Carter B. H. et al. Journal of Clinical Oncology 06-2011 – Johns Hopkins
Bokhorst L. P. et al. European Urology 06-2016 In Press - PRIAS
Christopher J. D. et al. European Urology 10-2015
Perspectivas Futuras
Lane A. J. and Donovan J. L.et al Lancet 08-2014 ProtecT Trial
AS in selected patients is feasible with an estimated 10‐year
PCa‐specific survival, reported between 96% and 100% for both
low‐ and intermediate‐risk patients.
However, the long natural history of PCa must be born in
mind, and even non‐PSA detected localized PCa has an indolente
course during the first 10–15 years with a cause specific
survival >90% when managed on WW.
Frederik B. Thomsen
[email protected]